Publications

These are publications from work undertaken by Frontier Science (Scotland).

O Metzger-Filho;  A Tutt; E. de Azambuja; K S Saini; G Viale; S Loi; I Bradbury; J M Bliss; H A Azim Jr; P Ellis; A Leo; J Baselga; C Sotiriou; M Piccart-Gebhart;  2012

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

Journal of Clinical Oncology,  Volume 30, Issue 15, Pages 1879-1887, doi:10.1200/JCO.2011.38.2010


M Piccart-Gebhart;  M Procter; B Leyland-Jones; A Goldhirsch; M Untch; I Smith; L Gianni; J Baselga; R Bell; C Jackisch; D Cameron; M Dowsett; C H Barrios; G Steger; C S Huang; M Andersson; M Inbar; M Lichinitser; I Lang; U Nitz; H Iwata; C Thomssen; C Lohrisch; T M Suter; J. Rüschoff; T Suto; V Greatorex; C Ward; C Straehle; E McFadden; M S Dolci; RD Gelber;  2005

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

The New England Journal of Medicine,  Volume 353, Issue 16, Pages 1659-1672, doi:10.1056/NEJMoa052306


E McFadden;  2007

Management of Data in Clinical Trials, Second Edition

Wiley , 


J Baselga;  I Bradbury; H. Eidtmann; S Di Cosimo; E. de Azambuja; C Aura; H Gomez; P Dinh; K Fauria; V Van Dooren; G Aktan; A Goldhirsch; T W Chang; Z Horvath; M Coccia-Portugal; J Domont; L M Tseng; G Kunz; J H Sohn; V Semiglazov; G Lerzo; M Palacova; V Probachai;  2012

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomized, open-label, multicentre, phase 3 trial

The Lancet,  Volume 379 : 9816 Pages 633-640, doi:10.1016/S0140-6736(11)61847-3


O Metzger-Filho;  E. de Azambuja; I Bradbury; K S Saini; J Bines; S Simon; V Van Dooren; G Aktan; KI Pritchard; AC Wolff; I Smith; C Jackisch; I Lang; M Untch; F Boyle; B Xu; J Baselga; EA Perez; M Piccart-Gebhart;  2013

Analysis of Regional timelines to set up a global phase III Clinical Trial in Breast Cancer: the Adjuvant Lapatinib and/ or Trastuzumab treatment optimization experience

The Oncologist,  Volume 18, Issue 2, Pages 134-140, doi:10.1634/theoncologist.2012-0342


H A Azim Jr;  D Agbor-Tarh; I Bradbury; P Dinh; J Baselga; S Di Cosimo; J G Greger; I Smith; C Jackisch; S Kim; B Aktas; C S Huang; P Vuylsteke; R K Hsieh; L Dreosti; H. Eidtmann; M. Piccart; E. de Azambuja;  2013

Pattern of Rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial

Journal of Clinical Oncology,  Volume 31, Issue 36, Pages 4504-4511, doi:10.1200/JCO.2013.50.9448


B C Pestalozzi;  E Holmes; E. de Azambuja; O Metzger-Filho; L Hogge; M Scullion; I Lang; A Wardley; M Lichinitser; R I Lopez-Sanchez; V Muller; D Dodwell; RD Gelber; M Piccart-Gebhart; D Cameron;  2013

CNS Relapses in Patients with HER2-positive early breast cancer who have and who have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

The Lancet Oncology,  Volume 14, Issue 3, Pages 244-248, doi:10.1016/S1470-2045(13)70017-2


A H Partridge;  S Gelber; M Piccart-Gebhart; F Focant; M Scullion; E Holmes; E P Winer; RD Gelber;  2013

Effect of Age on Breast Cancer outcomes in Women with HER-2 positive Breast Cancer: Results from a Herception Adjuvant Trial

Journal of Clinical Oncology,  Volume 31, Issue 21, Pages 2692-2698, doi:10.1200/JCO.2012.44.1956


S Loibl;  I J Majewski; V Guarneri; V Nekljudova; E Holmes; E Bria; C Denkert; C Schem; C Sotiriou; S Loi; M Untch; P Conte; R Bernards; M. Piccart; G von Minckwitz; J Baselga;  2016

PIK3CA Mutations are Associated with reduced pathological complete response rates in primary HER2-positive breast cancer-pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

Annals of Oncology,  Volume 27, Issue 8, Pages 1519-1525, doi:10.1093/annonc/mdw197


P Nuciforo;  C Aura; E Holmes; L Prudkin; J Jimenez; P Martinez; H Ameels; L de la Pena; CE Ellis; H. Eidtmann; M. Piccart; M Scaltriti; J Baselga;  2015

Benefit to Neoadjuvant anti-Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) Status

Annals of Oncology,  Volume 26, Issue 7, Pages 1494-1500, doi:10.1093/annonc/mdv175